Metabolic Effects of Starting Heart Failure Therapies
Part of Heart & circulation clinical trials.
This trial looks at how starting new heart failure treatments affects your body's metabolism. It may be an option if you have stable heart failure and haven't taken certain newer medicines before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with heart failure for more than 3 months
- You have symptoms like shortness of breath or fatigue that limit your daily activities
- You have not been hospitalized for heart failure in the past month
- You have not taken certain heart failure medicines (like SGLT2 inhibitors) in the past 3 months
- You have not had a recent heart procedure or blood transfusion in the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how metabolic changes, diet, and lifestyle patterns affect heart failure. It may help find ways to improve symptoms and health by targeting diet and daily habits.
This study tests an experimental medicine called NNC0537-1482 for people with heart failure. It aims to see if the medicine helps improve symptoms and heart function.
This study tests whether patients whose heart failure has improved can safely reduce some of their medications. If your heart function has recovered significantly and stayed stable, this trial explores whether you can gradually lower doses of heart failure drugs while staying healthy.
This trial tests whether it is safe and effective to increase heart failure medications (like ACE inhibitors, ARBs, ARNIs, MRAs, or SGLT-2 inhibitors) without frequent kidney monitoring. It is for people with heart failure and reduced ejection fraction who are not yet on full doses of these medicines.
This trial is a registry that will follow people with different types of chronic heart failure to better understand how heart health and metabolism are linked. It may help doctors improve care for future patients.
This trial tests whether a type of diabetes medicine called SGLT2 inhibitors can lower inflammation and stress markers in people with heart failure. It may help reduce damage to the heart and improve symptoms.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.